Fig. 3
From: Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastases
Association between progression-free survival (PFS) and a absolute decrease in volume between baseline MRI and day + 1 MRI, and b relative decrease in volume between baseline MRI and day + 1 MRI
